RxDoctor Payments DataLook up a doctor →

Sharon Scherl, MD

Dermatology · Tenafly, NJNPI 1770515595

Payments from drug & device makers

$87,268in general payments, 2019–2025

Across 1,216 payments — averaging $71.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dermavant Sciences, Inc.$55K
  • VYNE Pharmaceuticals Inc.$10K
  • Journey Medical Corporation$3K
  • AbbVie$2K
  • EPI Health, LLC$2K
  • Sun Pharmaceutical Industries Inc.$2K
  • plus $13K from 36 others

What the payments were for

  • Consulting fees$2,7903%
  • Speaking & faculty fees$63,07572%
  • Travel & lodging$1,6442%
  • Food & beverage$19,20322%
  • Education$5561%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,268 in reported general payments places this provider in the 90th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$459,770
Medicare patients
1,577
Services billed
9,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast24$110,667
Enbrel SureclickEtanercept12$86,445
Fluocinonide157$4,772
Ketoconazole182$3,430
Metronidazole35$2,879
Triamcinolone Acetonide183$2,124
Hydrocortisone223$2,050
Doxycycline Hyclate70$1,872
Clobetasol Propionate44$1,637
Mometasone Furoate84$1,508
Betamethasone Dipropionate41$1,088
Minoxidil77$864
Ammonium Lactate38$709
Hydrocortisone Valerate15$482
ValacyclovirValacyclovir Hcl19$443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$858$110,66724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 394 dermatology providers in New Jersey.

Other dermatology in Tenafly

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →